MetaVia (MTVA)
Clinical developer of obesity and MASH therapies.
Something off on this page? Send us feedback.
Develops DA-1726, a once-weekly injectable obesity candidate, and vanoglipel, a once-daily oral MASH candidate, through clinical development. Its pre-revenue model relies on licensed assets, external trial vendors, and Dong-A ST manufacturing support.
Develops two licensed cardiometabolic candidates: DA-1726, a once-weekly injectable dual GLP-1/glucagon agonist for obesity, and vanoglipel, a once-daily oral GPR119 agonist for MASH and potential type 2 diabetes combinations. Both remain in clinical development; no product is approved or generates revenue.
Operates from Cambridge, Massachusetts, and holds rights to the principal candidates outside Korea, while Dong-A ST retains specified Asian-Pacific territories. Work centers on advancing clinical programs, FDA interactions, and combination opportunities for vanoglipel; ANA001, NB-01, NB-02, and gemcabene are held for out-licensing or divestiture.
Uses a small internal team with CROs and other vendors for trial execution. Dong-A ST originated the two lead assets, provides technical and development support, and manufactures all clinical requirements.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $12.6M · Total debt $177.0K · Total assets $13.3M · Shareholders' equity $6.8M
- Revenue
- $0
- Operating income
- −$5.4M
- Net income
- −$5.3M
No dividends on record.
| Institutions12 holders · as of Mar 31, 2026 | 1.30% | 67.0K shares | |
| Insiders8 holders · as of Jun 8, 2026 | 3.77% | 194.8K shares | |
| Strategic holders1 holder · as of May 20, 2025 | 17.60% | 908.7K shares | |
| Otherremainder | 77.33% | 3.99M shares |
5.16M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (5.16M in the company's Sep 3, 2026 report, 2.20M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Dong-A St Co., LtdStrategic10 percent owner | 17.60% | 908,698 | Form 4filed May 20, 2025 ↗ |
Alyeska Investment Group, L.P.Institution | 9.85% | 508,585 | 13Gfiled May 15, 2026 ↗ |
Hyung Heon KimInsiderdirector, officer: CEO & President | 0.73% | 37,545 | Form 4filed Jan 27, 2026 ↗ |
Geode Capital Management, LLCInstitution | 0.65% | 33,635 | 13Fas of Mar 31, 2026 |
Marshall H. WoodworthInsiderofficer: Chief Financial Officer | 0.60% | 30,734 | Form 4filed Jan 27, 2026 ↗ |
| See all 23 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Novo Nordisk (ADR)
Marketed semaglutide spans the obesity and MASH battlefields.
- Eli Lilly
Marketed tirzepatide leads obesity while advancing in MASH.
- Madrigal Pharmaceuticals
Marketed oral Rezdiffra sets the MASH standard of care.
- Altimmune
Dual GLP-1/glucagon pemvidutide overlaps in obesity and MASH.
- Viking Therapeutics
Late-stage obesity and MASH programs contend across both lead markets.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| MetaVia | $1.78 | −3.26% | $4.0M | — | — | — | — |
| Novo Nordisk (ADR) | $47.45 | +1.49% | $207.69B | 11.5 | 18.9 | 4.1 | +0.0% |
| Eli Lilly | $1,160.08 | +0.06% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Madrigal Pharmaceuticals | $546.41 | +1.43% | $12.64B | — | — | 9.8 | +71.2% |
| Altimmune | $3.27 | −0.15% | $637.9M | — | — | 20,576.6 | +820.0% |
| Viking Therapeutics | $32.98 | −1.55% | $3.91B | — | — | — | — |
| Median | 25.2 | 23.6 | 11.8 | +59.4% |